Therapeutic Antibodies
Subscribe to
our newsletters!
Showing 21–38 of 38 resultsSorted by latest
-
On demand upon order placementThis competitive intelligence report about c-Met-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting c-Met.€ 300.00
-
On demand upon order placementThis competitive intelligence report about Her3-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting Her3.€ 300.00
-
August of 2025This competitive intelligence report about DLL3-Targeted Therapy provides a competitor evaluation in the field of product candidates targeting delta-like ligand 3 (DLL3) as of August of 2025.€ 300.00
-
August of 2025This competitive intelligence report about B7-H3 Targeted Therapy provides a competitor evaluation in the field of product candidates targeting B7-H3 (or CD276) as of August of 2025.€ 300.00
-
July of 2025This competitive intelligence report about GPC3 Targeted Therapy provides a competitor evaluation in the field of product candidates targeting glypican-3 (GPC3) as of July of 2025.€ 400.00
-
July of 2025This competitive intelligence report about Fibroblast Activation Protein (FAP) Targeted Therapy provides a competitor evaluation in the field of product candidates targeting Fibroblast Activation Protein (FAP) as of July of...€ 300.00
-
July of 2025This competitive intelligence report Folate Receptor alpha (FRα) Targeted Therapy provides a competitor evaluation in the field of product and product candidates targeting Folate Receptor alpha as of July of...€ 200.00
-
July of 2025This competitive intelligence report about TL1A Inhibitors and DR3 Antagonists provides a competitor evaluation in the field of mostly antibodies targeting TNF-like ligand 1A (TL1A) or death receptor 3 (DR3) as...€ 200.00
-
July of 2025This competitive intelligence report about TSLP Inhibitors and TSLP Receptor Antagonists provides a competitor evaluation in the field of mostly antibodies targeting Thymic Stromal Lymphopoietin (TSLP) or its receptor as of...€ 300.00
-
June of 2025Landscape analysis of Vectorized antibodies by in vivo expression of DNA or RNA regarding stakeholders, R&D pipeline, profile & composition of drug candidates and business deals from an industry perspective...€ 2600.00
-
March of 2025This Competitive Intelligence report about PSMA-Targeted Therapy & Radiodiagnostics provides a competitor evaluation in the field of imaging of PSMA-positive prostate cancer and of PSMA-targeted therapy as of March of 2025€ 500.00
-
March of 20252024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNAOriginal price was: € 130.00.€ 117.00Current price is: € 117.00.
-
February of 2025Report with a landscape analysis of PD-(L)1 x VEGF(R) bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective...€ 2000.00
-
September of 2024Degrader-Antibody Conjugates 2024: Stakeholders, Technologies, Pipeline and Deals€ 2050.00
-
March of 20242023 sales data of originator therapeutic proteins and antibodies, selected biosimilars and other biologic drug modalities (gene & cell therapy, RNA)€ 130.00
-
August of 2023This report provides a landscape description and analysis of discovery and development of claudin 18.2 (CLDN18.2)-targeted antibody and cell therapy candidates from an industry perspective as of August 2023Original price was: € 2150.00.€ 1720.00Current price is: € 1720.00.
-
July of 2022This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.Original price was: € 2550.00.€ 1800.00Current price is: € 1800.00.
-
May of 2022This report describes and analyzes cadherin 17 (CDH17) as a target opportunity for development of effector-enhanced drug modalities€ 400.00